Oxytocin

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Protein

www.ebi.ac.uk

First approval year

1980

www.ebi.ac.uk

First approval year: 1980
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Protein
www.ebi.ac.uk

Drug name: Oxytocin
www.ebi.ac.uk

Molecular weight: 1,007.21
www.ebi.ac.uk

Structure (SMILES): CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
www.ebi.ac.uk

orasthin
Orasthin
oxytocin
Oxytocin
pitocin
Pitocin
syntocinon
Syntocinon
syntometrine
Syntometrine

1 iu intravenous oxytocin
1 IU intravenous oxytocin
10 units Oxytocin
2.5 units Oxytocin
alpha hypophamine
alpha hypophamine who ip
Alpha-hypophamine
ALPHA-HYPOPHAMINE [WHO-IP]
endopituitrina
Endopituitrina
glycinamide l cysteinyl l tyrosyl l isoleucyl l glutaminyl l asparaginyl l cysteinyl l prolyl l leucyl cyclic 1 6 disulfide
GLYCINAMIDE, L-CYSTEINYL-L-TYROSYL-L-ISOLEUCYL-L-GLUTAMINYL-L-ASPARAGINYL-L-CYSTEINYL-L-PROLYL-L-LEUCYL-, CYCLIC (1->6)-DISULFIDE
intertocine s
Intertocine s
intravenous & intramuscular oxytocin
intravenous oxytocin
Intravenous oxytocin
Intravenous Oxytocin
Intravenous oxytocin infusion
Intravenous Syntocinon
IV Oxytocin
Oral oxytocin
Oral Oxytocin
oxitocina
Oxitocina

And 71 more, listed on the interactive page.

ATC classification codes

H01BB02

Sources for recorded values

www.ebi.ac.uk

CAS registry numbers

50-56-6

ChEMBL ID: CHEMBL395429
www.ebi.ac.uk

InChIKey: XNOPRXBHLZRZKH-DSZYJQQASA-N
www.ebi.ac.uk

PubChem compound IDs

439302

FDA ingredient codes (UNII)

1JQS135EYN

7824
1733680

Applicant: FRESENIUS KABI USA
Approval date: 9 Jul 1980
Application number: NDA018248

Patents: 0
Designations: 2
First in class: No
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: No
Orphan exclusivity: No
Accelerated approval: No
Availability: Prescription only
Boxed warning: Yes

Pharmacology name: oxytocin
Type: Peptide
Drug name stem: -tocin
Approval recorded by Guide to Pharmacology: Yes

Administration routes

Parenteral
topical

Mechanism
Oxytocin receptor agonist
Action type
Agonist
Target
Oxytocin receptor
Protein identifier
P30559
Action
Full agonist
Action type
FULL_AGONIST
Target
V2 receptor
Gene symbol
AVPR2
Protein identifier
P30518
Affinity units
pKi
Action
Full agonist
Action type
FULL_AGONIST
Target
OT receptor
Gene symbol
OXTR
Protein identifier
P30559
Affinity units
pKi
Primary target
Yes
Action
Full agonist
Action type
FULL_AGONIST
Target
V1A receptor
Gene symbol
AVPR1A
Protein identifier
P37288
Affinity units
pKi
Action
Full agonist
Action type
FULL_AGONIST
Target
V1B receptor
Gene symbol
AVPR1B
Protein identifier
P47901
Affinity units
pKi

Open Targets mechanisms

Mechanism
Oxytocin receptor agonist
Action type
Agonist
Target
Oxytocin receptor

DrugCentral mechanisms

Action type
Agonist
Gene symbol
OXTR
Protein identifier
P30559
Organism
Homo sapiens
Target development level
Clinical

Condition
Carcinoma, Intraductal, Noninfiltrating
Highest recorded phase
2
Condition identifier
EFO:0000432
Subject identifier
D002285
Condition
Myocardial Infarction
Highest recorded phase
2
Condition identifier
EFO:0000612
Subject identifier
D009203
Condition
Pre-Eclampsia
Highest recorded phase
0.5
Condition identifier
EFO:0000668
Subject identifier
D011225
Condition
Obesity
Highest recorded phase
2
Condition identifier
EFO:0001073
Subject identifier
D009765
Condition
Stress Disorders, Post-Traumatic
Highest recorded phase
2
Condition identifier
EFO:0001358
Subject identifier
D013313
Condition
Cocaine-Related Disorders
Highest recorded phase
2
Condition identifier
EFO:0002610
Subject identifier
D019970
Condition
Child Development Disorders, Pervasive
Highest recorded phase
3
Condition identifier
EFO:0003756
Subject identifier
D002659
Condition
Autistic Disorder
Highest recorded phase
2
Condition identifier
EFO:0003758
Subject identifier
D001321
Condition
Pain
Highest recorded phase
2
Condition identifier
EFO:0003843
Subject identifier
D010146
Condition
Sleep Apnea Syndromes
Highest recorded phase
1
Condition identifier
EFO:0003877
Subject identifier
D012891
Condition
Attention Deficit Disorder with Hyperactivity
Highest recorded phase
0.5
Condition identifier
EFO:0003888
Subject identifier
D001289
Condition
Substance-Related Disorders
Highest recorded phase
2
Condition identifier
EFO:0003890
Subject identifier
D019966
Condition
Sleep Apnea, Obstructive
Highest recorded phase
2
Condition identifier
EFO:0003918
Subject identifier
D020181
Condition
Obsessive-Compulsive Disorder
Highest recorded phase
2
Condition identifier
EFO:0004242
Subject identifier
D009771
Condition
Mood Disorders
Highest recorded phase
2
Condition identifier
EFO:0004247
Subject identifier
D019964
Condition
Arrhythmias, Cardiac
Highest recorded phase
0.5
Condition identifier
EFO:0004269
Subject identifier
D001145
Condition
Weight Gain
Highest recorded phase
2
Condition identifier
EFO:0004566
Subject identifier
D015430
Condition
Osteoarthritis, Knee
Highest recorded phase
2
Condition identifier
EFO:0004616
Subject identifier
D020370
Condition
Sexual Dysfunction, Physiological
Highest recorded phase
2
Condition identifier
EFO:0004714
Subject identifier
D012735
Condition
Substance Withdrawal Syndrome
Highest recorded phase
2
Condition identifier
EFO:0004777
Subject identifier
D013375
Condition
Feeding and Eating Disorders
Highest recorded phase
2
Condition identifier
EFO:0005203
Subject identifier
D001068
Condition
Psychotic Disorders
Highest recorded phase
1
Condition identifier
EFO:0005411
Subject identifier
D011618
Condition
Opioid-Related Disorders
Highest recorded phase
1
Condition identifier
EFO:0005611
Subject identifier
D009293
Condition
Neuralgia
Highest recorded phase
2
Condition identifier
EFO:0005762
Subject identifier
D009437
Condition
Postpartum Hemorrhage
Highest recorded phase
3
Condition identifier
EFO:0009579
Subject identifier
D006473

And 28 more, listed on the interactive page.

Condition identifier
EFO_0000246
Condition identifier
EFO_0000612
Condition identifier
EFO_0000668
Condition identifier
EFO_0001073
Highest recorded phase
2
Condition identifier
EFO_0001358
Highest recorded phase
2
Condition identifier
EFO_0002610
Condition identifier
EFO_0002950
Condition identifier
EFO_0003756
Condition identifier
EFO_0003758
Highest recorded phase
2
Condition identifier
EFO_0003768
Condition identifier
EFO_0003877
Highest recorded phase
1
Condition identifier
EFO_0003888
Condition identifier
EFO_0003890
Highest recorded phase
3
Condition identifier
EFO_0003918
Highest recorded phase
2
Condition identifier
EFO_0003925
Highest recorded phase
1
Condition identifier
EFO_0003958
Highest recorded phase
2
Condition identifier
EFO_0004242
Highest recorded phase
2
Condition identifier
EFO_0004247
Highest recorded phase
2
Condition identifier
EFO_0004269
Condition identifier
EFO_0004566
Highest recorded phase
2
Condition identifier
EFO_0004616
Highest recorded phase
2
Condition identifier
EFO_0004714
Highest recorded phase
2
Condition identifier
EFO_0004777
Highest recorded phase
2
Condition identifier
EFO_0005203
Highest recorded phase
2
Condition identifier
EFO_0005611

And 113 more, listed on the interactive page.

Warnings

Warning
Black Box Warning

Open Targets warnings

Warning
Black Box Warning
Country
United States

Event
activated partial thromboplastin time prolonged
Reports
7
Reporting signal score
12.7353
Event
acute pulmonary oedema
Reports
11
Reporting signal score
26.2018
Event
acute right ventricular failure
Reports
2
Reporting signal score
8.77716
Event
amniotic cavity infection
Reports
6
Reporting signal score
22.0258
Event
amniotic fluid embolus
Reports
3
Reporting signal score
22.9285
Event
anaphylactic reaction
Reports
42
Reporting signal score
60.5397
Event
anaphylactic shock
Reports
12
Reporting signal score
13.4733
Event
anaphylactoid syndrome of pregnancy
Reports
2
Reporting signal score
10.4923
Event
apgar score low
Reports
17
Reporting signal score
67.8678
Event
apnoea
Reports
6
Reporting signal score
8.98611
Event
artificial rupture of membranes
Reports
6
Reporting signal score
41.7092
Event
assisted delivery
Reports
2
Reporting signal score
12.2776
Event
asthenia
Reports
2
Reporting signal score
11.1049
Event
bradycardia
Reports
25
Reporting signal score
20.8617
Event
bradycardia foetal
Reports
25
Reporting signal score
120.737
Event
bradycardia neonatal
Reports
4
Reporting signal score
10.6881
Event
brief psychotic disorder, with postpartum onset
Reports
2
Reporting signal score
9.50979
Event
caesarean section
Reports
68
Reporting signal score
226.466
Event
cardiac arrest
Reports
13
Reporting signal score
12.9347
Event
cardiac output increased
Reports
8
Reporting signal score
43.7102
Event
central venous pressure increased
Reports
2
Reporting signal score
8.93654
Event
cerebral palsy
Reports
4
Reporting signal score
14.1561
Event
cerebrovascular spasm
Reports
3
Reporting signal score
13.245
Event
cervix disorder
Reports
3
Reporting signal score
10.2195
Event
convulsion neonatal
Reports
3
Reporting signal score
9.28564

And 97 more, listed on the interactive page.

NCT00263796
clinicaltrials.gov
NCT00490802
clinicaltrials.gov
NCT01183221
clinicaltrials.gov
NCT01308749
clinicaltrials.gov
NCT01624194
clinicaltrials.gov
NCT01912378
clinicaltrials.gov
NCT03033784
clinicaltrials.gov
NCT03183674
clinicaltrials.gov
NCT00663039
clinicaltrials.gov
NCT00813436
clinicaltrials.gov
NCT01012167
clinicaltrials.gov
NCT01394471
clinicaltrials.gov
NCT01517360
clinicaltrials.gov
NCT01568528
clinicaltrials.gov
NCT01699997
clinicaltrials.gov
NCT01712646
clinicaltrials.gov
NCT01987050
clinicaltrials.gov
NCT02566356
clinicaltrials.gov
NCT02567032
clinicaltrials.gov
NCT02568709
clinicaltrials.gov
NCT02577575
clinicaltrials.gov
NCT03900754
clinicaltrials.gov
NCT00776360
clinicaltrials.gov
NCT00785395
clinicaltrials.gov
NCT00884897
clinicaltrials.gov

And 152 more, listed on the interactive page.

Dose: 1-10 drops
Route: Sublingual
How often: 3 times a day or as directed by a health professional

Conditions of use

Consult a physician for use in children under 12 years of age

Calculated partition coefficient (XLogP): -2.6
Prodrug: No
Chirality: Single enantiomer
Inorganic: No
Heavy atoms: 69
Molecular formula: C43H66N12O12S2
Monoisotopic mass: 1006.43645793
Natural product: Yes

0143-9742
0143-9743
42023-116
42023-130
63323-012
65219-021
55154-9584

Recorded assays: 374
Active assays: 103

Confirmatory
Other

Oxytocics
id.nlm.nih.gov

Oral bioavailability

Median: 0.85
Mean: 0.85
Minimum: 0.85
Maximum: 0.85
Unit: %
Assays: 1
Standard deviation: 0
Summary method: median
Censored results excluded: 0
Other units excluded: 0
Unknown units excluded: 0

Measurement types

Related records

Trials (820)

"The Effects of Oxytocin on Patients With Borderline Personality Disorder"
18850 - Human Photoallergy Test
3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis
A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Patients
A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis
A Comparison of Balloon Catheter Versus Ocytocin for Cervical Ripening on Scarred Uterus With Unfavorable Cervix
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis
A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
A Drug Safety and Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV Treatment
A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers
A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia
A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking
A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001
A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia
A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects
A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin
A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)
A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray
A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis

In development for (47)

Alcohol dependence Phase 3
Alcohol withdrawal Phase 2
Anorexia nervosa Early phase 1
Anxiety disorder Phase 2
Attention deficit-hyperactivity disorder Early phase 1
Autism Phase 2
Autism spectrum disorder Phase 3
Benign muscle neoplasm Phase 3
Cardiac rhythm disease Early phase 1
Cocaine dependence Phase 2
COVID-19 Phase 2
Depressive disorder Phase 2
Diabetes insipidus Phase 1
Drug dependence Phase 2
Ductal breast carcinoma in situ Phase 2
Dystocia Phase 3
Eating disorder Phase 2
Fragile X syndrome Phase 2
Frontotemporal dementia Phase 2
Gastroparesis Early phase 1

Targets (1)

OXTR Oxytocin receptor agonist

Oxytocin

Development status

Names and chemistry

Brand names (10)

Other names (96)

Identifiers

RxNorm IDs (RxCUI) (2)

Regulatory information

United States

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action (5)

Open Targets mechanisms

DrugCentral mechanisms

Investigated indications (53)

Open Targets indications (138)

Warnings

Open Targets warnings

Reported adverse events (122)

Trial references (177)

Dosing

Conditions of use

Chemical properties

National Drug Codes

Evidence counts

Active assay types (2)

Pharmacologic actions

Biological measurements

Observed measurements

Oral bioavailability

Measurement types

Related records

Trials (820)

In development for (47)

Other linked conditions (3)

Targets (1)